Clinical trials: Renal Anemia
Healthy Volunteers
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
- Trial name
- NCT02062203
- Testing
- AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Atypical Hemolytic-Uremic Syndrome
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
The record Primary purpose is to assess the efficacy of eculizumab in adult patients with Atypical Hemolytic- Uremic Syndrome (aHUS) to control Thrombotic Microangiopathy (TMA) as characterized by thrombocytopenia, hemolysis and…
- Trial name
- NCT01194973
- Testing
- Eculizumab
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 44 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Anemia, Chronic Kidney Disease (CKD)
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously.
- Trial name
- ACCESS (NCT01693029)
- Testing
- HX575 epoetin alfa, US-licensed epoetin alfa
- Where
- 52 sites in United States
- Volunteers
- 435 people
- Sponsor
- Sandoz
Anemia
A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis
This study will evaluate the effect of epoetin beta (NeoRecormon) on correction of anemia and quality of life in participants with diabetes and chronic renal failure and who are not receiving dialysis.
- Trial name
- NCT02827266
- Testing
- Epoetin beta
- Where
- 78 sites in France
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia.
- Trial name
- NCT00661505
- Testing
- methoxy polyethylene glycol-epoetin beta
- Where
- 20 sites in Turkey (Türkiye)
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Renal Anemia
Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
This sequential study will assess the efficacy and safety of multiple doses of intravenous (IV) methoxy polyethylene glycol-epoetin beta (MIRCERA), and will determine the optimum starting dose for maintenance treatment of anemia…
- Trial name
- NCT00717366
- Testing
- Methoxy Polyethylene Glycol-Epoetin Beta
- Where
- 39 sites in Australia, Belgium and 10 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
This 2 arm study will compare the hemoglobin maintenance with once monthly methoxy polyethylene glycol-epoetin beta (Mircera) administration versus epoetin beta or darbepoetin alfa in participants with chronic kidney disease on…
- Trial name
- NCT00717821
- Testing
- Methoxy Polyethylene Glycol-epoetin Beta, Epoetin Beta, Darbepoetin Alfa
- Where
- 89 sites in France
- Volunteers
- 421 people
- Sponsor
- Hoffmann-La Roche
Anemia Associated With Chronic Kidney Disease (CKD)
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
This study will be conducted to demonstrate the efficacy and safety of vadadustat administered three times weekly (TIW) compared to a long-acting erythropoiesis-stimulating agent (ESA) (Mircera®) for the maintenance treatment of…
- Trial name
- NCT04707768
- Testing
- Vadadustat, Mircera®
- Where
- 58 sites in United States
- Volunteers
- 456 people
- Sponsor
- Akebia Therapeutics
Anemia
A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
This single arm study assessed the efficacy and safety of subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera), a continuous erythropoietin receptor activator (C.E.R.A.), for correction and/or maintenance of hemoglobin…
- Trial name
- NCT00642668
- Testing
- methoxy polyethylene glycol-epoetin beta
- Where
- 32 sites in Belgium
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
aHUS, Atypical Hemolytic Uremic Syndrome
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).
- Trial name
- NCT07308574
- Testing
- Ravulizumab
- Where
- 12 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
This is an international, multicenter trial, evaluating pharmacokinetics (PK) (4 weeks), safety (52 weeks), and hemoglobin (Hgb) response (52 weeks) to daprodustat in children and adolescent participants with anemia associated…
- Trial name
- ASCEND-P (NCT05682326)
- Testing
- Daprodustat
- Where
- 4 sites in Japan, South Korea
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Renal Anemia
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
- Trial name
- NCT05265325
- Testing
- AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
- Where
- 25 sites in United States, China
- Volunteers
- 175 people
- Sponsor
- Kind Pharmaceuticals LLC
Anemia
A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.
This single arm study will assess the efficacy, safety and tolerability of subcutaneous C.E.R.A. for correction of anemia and maintenance of hemoglobin levels in patients with chronic kidney disease who are not on dialysis and…
- Trial name
- NCT00576628
- Testing
- methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
- Where
- 19 sites in Russia
- Volunteers
- 133 people
- Sponsor
- Hoffmann-La Roche
Atypical Hemolytic Uremic Syndrome
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.
- Trial name
- NCT05795140
- Testing
- Iptcaopan 200 mg
- Where
- 9 sites in Brazil, China and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease on Dialysis (HORTENSIA)
This observational study will evaluate the course of treatment, the efficacy on anemia and the safety of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease on dialysis.
- Trial name
- NCT01213485
- Where
- France
- Volunteers
- 419 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Anemia
Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
This is a Phase 1b, randomized, double-blinded, placebo-controlled study of CTX001 in participants with anemia and chronic kidney disease who are not on dialysis.
- Trial name
- NCT07901933
- Testing
- CTX001, Ferrous Sulfate
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Cajal Therapeutics Inc.
Anemia, Chronic Kidney Disease
Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease
The purpose of this study is to find out more about darbepoetin alfa in children less than 1 year of age with anemia (a decrease in red blood cells) due to kidney failure.
- Trial name
- NCT01428154
- Testing
- Darbepoetin alfa
- Sponsor
- Amgen
Anemia
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis.
- Trial name
- NCT00048048
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Anaemia
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
- Trial name
- NCT02876835
- Testing
- Daprodustat, Darbepoetin alfa, Iron Therapy
- Where
- 574 sites in United States, Argentina and 37 more
- Volunteers
- 3,872 people
- Sponsor
- GlaxoSmithKline
Anemia
STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in dialysis participants with chronic renal anemia.
- Trial name
- NCT00642850
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 24 sites in Czechia
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche